Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-APOC3 Open-Label Extension in Adults With Dyslipidemia
NCT05413135Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Sep 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 7
01
Overview
A Phase 2 trial of plozasiran in dyslipidemia, sponsored by Arrowhead Pharmaceuticals. Started Jul 2022; status: completed.
02
Drugs
plozasiran
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT05413135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413135.